<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The aim of this study is to raise <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressing monoclonal antibodies (mAbs) against colorectal <z:mp ids='MP_0002038'>carcinomas</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we generated a novel mAb 3P9, targeted a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-associated carbohydrate antigen sialyl-Tn (sTn), which showed significant inhibitory effect on proliferation and migration of sTn cells and <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> by inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="2" pm="."><plain>We also demonstrated that mAb 3P9 showed higher sensitivity and specificity in immunohistochemistry assay on <z:mp ids='MP_0009314'>colonic adenocarcinoma</z:mp> than the broadly used commercial anti-sTn antibody B72.3 </plain></SENT>
<SENT sid="3" pm="."><plain>These results provide the first evidence that mAb 3P9 has potential applications, not only for diagnosis but also for antibody-based <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> therapy </plain></SENT>
</text></document>